REMAP-CAP Trial

All Done!

A bit more to do?    Log in


The latest from the Spiral blog . . .

TTM2 Trial: Hypothermia vs. Normothermia after Out-of-Hospital Cardiac Arrest

2021-06-29


A project in Spiral’s study manifest, has recently been used in the long-awaited TTM2 trial. After successful resuscitation, patients who survive a cardiac arrest often remain severely ill and require intensive care. Controlling body temperature is a potential treatment that may prevent brain damage. The TTM2-trial aimed to study the impact on all-cause mortality of targeted hypothermia compared with targeted normothermia.

  
 

Follow us on Twitter
     
 

Like us on Facebook



 

REMAP-CAP

REMAP-CAP is a Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia. The primary aim of the study is to identify the effect of a range of interventions to improve all-cause mortality at 90 days.

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.

This instance of REMAP-CAP hosted on our RELENTLESS server